Sotatercept
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Sotatercept
- Sotatercept: From Pulmonary Arterial Hypertension (Not Stated in Local Licence Data) to Acute Lymphoblastic Leukemia
Sotatercept: From Pulmonary Arterial Hypertension (Not Stated in Local Licence Data) to Acute Lymphoblastic Leukemia
One-Sentence Summary
Sotatercept is an activin receptor type IIA-Fc fusion protein that is marketed in Singapore as WINREVAIR®. The approved indication text is not available in the data compiled for this report. The TxGNN model predicts it may be effective for acute lymphoblastic leukemia, but there are currently 0 clinical trials and 0 publications supporting this direction, so this is a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (the approved indication text in the Singapore licences is empty) |
| Predicted New Indication | Acute lymphoblastic leukemia |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Sotatercept is an activin receptor type IIA-Fc fusion protein. It acts as a ligand trap for activin and growth differentiation factors (GDFs), which helps rebalance BMP/activin signaling. Detailed mechanism of action data is not available in the compiled data, so this description comes from the mechanistic notes prepared for this assessment.
No direct mechanistic link between this pathway and the biology of acute lymphoblastic leukemia was identified. The high TxGNN score (0.998) is a graph-based prediction only. A role for activin signaling in blood cell development is a speculative connection at best.
Other predicted indications are also unsupported by clinical evidence. They include:
- Drug-induced osteoporosis (score 99.65%): the most biologically coherent hypothesis, because activin A inhibition is relevant to bone metabolism. It remains a prediction.
- Diabetic retinopathy, including severe nonproliferative disease (99.77% and 99.72%): a plausible but unvalidated link through retinal vascular remodeling. The two entries overlap and are not independent confirmation.
- Urothelial carcinoma subtypes (ranks 7-10): a cluster of near-identical, graph-propagated predictions that should be treated as one correlated signal.
- Diabetic cataract and HER2 positive breast carcinoma: no clear mechanistic rationale. In breast cancer, activin/TGF-beta signaling can be either tumour-suppressive or pro-metastatic depending on context.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17094P | WINREVAIR® Powder for Solution for Injection 60 mg (vial only) | Lyophilized powder for injection | Not stated in the data |
| SIN17093P | WINREVAIR® Powder for Solution for Injection 45 mg (vial only) | Lyophilized powder for injection | Not stated in the data |
Safety Considerations
Please refer to the package insert for safety information.
For this class of drug, the mechanistic notes flag possible vascular effects such as bleeding or telangiectasia. These would need careful assessment in any new setting, especially retinal use. In oncology, the uncertain direction of activin/TGF-beta effects is itself a safety concern.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN graph score. There are no clinical trials or publications, and no mechanistic link to acute lymphoblastic leukemia was identified. The evidence level is L5.
To proceed, the following is needed:
- The Singapore package insert, to establish the approved indication, warnings and contraindications
- Detailed mechanism of action data
- A literature and trial search for the top-ranked indications, with drug-induced osteoporosis as the most biologically plausible candidate to examine first
- Review of bone-related findings in the sotatercept programme from primary sources
- A safety assessment of vascular effects before any retinal or oncology use
- An analysis of route and dosage compatibility for any new indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.